NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma
Gray-zone Lymphoma
Non-Hodgkin Lymphoma
Lymphoma
Primary Central Nervous System Lymphoma

Interventions: Biological: Pembrolizumab

First Posted Date: 2017-08-21

Last Posted Date: 2023-11-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03255018

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Phase 2

Completed

Conditions: Advanced Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Drug: Adavosertib

First Posted Date: 2017-08-18

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT03253679

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States

and more 6 locations

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

Phase 1

Active, not recruiting

Conditions: Prostate Cancer
Prostatic Neoplasm

Interventions: Drug: 18F-DCFPyL
Radiation: Tumor Irradiation
Radiation: Prostate + tumor irradiation

First Posted Date: 2017-08-18

Last Posted Date: 2024-11-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT03253744

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Rare CNS Tumors Outcomes &Risk

Suspended

Conditions: PNET
High Grade Meningioma
Medulloblastoma
Primary CNS Sarcoma
Ependymoma

First Posted Date: 2017-08-16

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 326

Registration Number: NCT03251989

Locations: 🇺🇸
National Cancer Institute (NCI)/ Neuro-Oncology Branch, Bethesda, Maryland, United States

Questionnaire Pre-Test Study

Completed

Conditions: Cancer

First Posted Date: 2017-08-14

Last Posted Date: 2020-04-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03248635

Locations: 🇺🇸
Social & Scientific Systems, INC, Durham, North Carolina, United States

Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection

Completed

Conditions: Hepatitis B

First Posted Date: 2017-08-14

Last Posted Date: 2023-11-30

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 79

Registration Number: NCT03248622

Locations: 🇺🇸
National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK), Bethesda, Maryland, United States

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Phase 3

Active, not recruiting

Conditions: Locally Advanced Ureter Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage II Ureter Cancer AJCC v7
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Localized Renal Pelvis and Ureter Urothelial Carcinoma
Locally Advanced Bladder Urothelial Carcinoma
Stage III Ureter Cancer AJCC v7
Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Stage II Renal Pelvis and Ureter Cancer AJCC v7
Stage III Renal Pelvis and Ureter Cancer AJCC v7

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Clinical Observation
Procedure: CT Urography
Procedure: Cystoscopy
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-08-09

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 739

Registration Number: NCT03244384

Locations: 🇺🇸
McFarland Clinic - Boone, Boone, Iowa, United States
🇺🇸
Saint Anthony Regional Hospital, Carroll, Iowa, United States
🇺🇸
Mercy Cancer Center-West Lakes, Clive, Iowa, United States

and more 913 locations

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Ureter Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Recurrent Ureter Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8
Stage III Ureter Cancer AJCC v8
Locally Advanced Urethral Urothelial Carcinoma
Recurrent Renal Pelvis Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Recurrent Bladder Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography with Contrast
Drug: Eribulin Mesylate

First Posted Date: 2017-08-03

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT03237780

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States

and more 18 locations

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Phase 3

Active, not recruiting

Conditions: Anal Basaloid Carcinoma
Anal Canal Cloacogenic Carcinoma
Anal Margin Squamous Cell Carcinoma
Stage IIB Anal Cancer AJCC v8
Stage III Anal Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Colonoscopy
Procedure: Computed Tomography
Procedure: Digital Rectal Examination
Procedure: High Resolution Anoscopy
Procedure: Magnetic Resonance Imaging
Other: Patient Observation
Biological: Nivolumab
Procedure: Proctoscopy
Procedure: Sigmoidoscopy
Procedure: X-Ray Imaging

First Posted Date: 2017-07-31

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 344

Registration Number: NCT03233711

Locations: 🇺🇸
Crossroads Cancer Center, Effingham, Illinois, United States
🇺🇸
Illinois CancerCare-Eureka, Eureka, Illinois, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 897 locations

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Phase 1

Terminated

Conditions: Lung Cancer
Carcinoma, Non-Small-Cell Lung
Carcinoma, Esophageal
Non-Small Cell Lung Cancer
Malignant Pleural Mesotheliomas

Interventions: Drug: Decitabine (DAC)
Drug: Tetrahydrouridine (THU)
Drug: Pembrolizumab

First Posted Date: 2017-07-31

Last Posted Date: 2023-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT03233724

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy